



Deuterium Depletion: From Basic Research to Novel Therapeutic Approaches

Guest Editor:

Dr. Gábor Somlyai

HYD LLC for Cancer Research and
Drug Development, 1118
Budapest, Hungary

Deadline for manuscript
submissions:

closed (29 February 2024)

Message from the Guest Editor

This Special Issue will mainly focus on the role of deuterium and/or the deuterium/hydrogen ratio in the regulation of cell cycle, cell metabolism and about the therapeutic efficacy of deuterium depletion in a wide range of indications. The issue will focus on deuterium depletion as a new drug development strategy and its clinical implementation. Submissions proving the efficacy of deuterium depletion in other indications will also fit the scope of the Special Issue.

Deuterium depletion is an emerging field of research. In *recent years, the number of publications* examining the effects of deuterium-depleted water (DDW) in different biological systems has increased across a wide array of fields, including cancer and metabolic disease research, depression, cognitive functions, and aging. The Special Issue of *Biomedicines* is a collection of papers centered around the basic and clinical research of deuterium depletion organized and led by subject experts.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)